Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuhiko Shirasaka

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Japanese Journal of Clinical Oncology|December 5, 2008
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistasTetsuhiko Shirasaka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 11, 2006
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]Tetsuhiko Shirasaka, Tetsuo Taguchi
Expert Opinion on Drug Delivery|January 13, 2012
S-1 as a core anticancer fluoropyrimidine agentKoh Miura, Tetsuhiko Shirasaka, Hiroki Yamaue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 17, 2012
[A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer]Yasushige Kashima, Takenori Adachi, Nobuhisa Hara, et al.
Surgery Today|July 10, 2008
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trialFumitake Hata, Kazuaki Sasaki, Koichi Hirata, et al.
BMC Cancer|May 9, 2006
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinomaKazuma Kobayashi, Akihito Tsuji, Sojiro Morita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902)Bunzo Nakata, Yasushi Mitachi, Akihito Tsuji, et al.
Cancer Chemotherapy and Pharmacology|December 1, 2005
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracilTetsuro Yamashita, Yuji Ueda, Nobuaki Fuji, et al.
Japanese Journal of Clinical Oncology|July 3, 2004
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic studyYuji Ueda, Hisakazu Yamagishi, Tetsuro Yamashita, et al.
Anti-Cancer Drugs|July 11, 2003
Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcomaYoshimasa Suzuki, Yoshiro Ishibiki, Ken Kawai, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Japanese Journal of Clinical Oncology|December 5, 2008
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistasTetsuhiko Shirasaka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 11, 2006
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]Tetsuhiko Shirasaka, Tetsuo Taguchi
Expert Opinion on Drug Delivery|January 13, 2012
S-1 as a core anticancer fluoropyrimidine agentKoh Miura, Tetsuhiko Shirasaka, Hiroki Yamaue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 17, 2012
[A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer]Yasushige Kashima, Takenori Adachi, Nobuhisa Hara, et al.
Surgery Today|July 10, 2008
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trialFumitake Hata, Kazuaki Sasaki, Koichi Hirata, et al.
BMC Cancer|May 9, 2006
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinomaKazuma Kobayashi, Akihito Tsuji, Sojiro Morita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902)Bunzo Nakata, Yasushi Mitachi, Akihito Tsuji, et al.
Cancer Chemotherapy and Pharmacology|December 1, 2005
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracilTetsuro Yamashita, Yuji Ueda, Nobuaki Fuji, et al.
Japanese Journal of Clinical Oncology|July 3, 2004
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic studyYuji Ueda, Hisakazu Yamagishi, Tetsuro Yamashita, et al.
Anti-Cancer Drugs|July 11, 2003
Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcomaYoshimasa Suzuki, Yoshiro Ishibiki, Ken Kawai, et al.
Pageof 4